AMARIN CORP PLC\UK Number of Reportable Segments
AMARIN CORP PLC\UK (AMRN) reported Number of Reportable Segments of 1 Segment for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-03-02
- AMARIN CORP PLC\UK number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment.
- AMARIN CORP PLC\UK number of reportable segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- AMARIN CORP PLC\UK number of reportable segments for fiscal 2024 was 1.00 Segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-02 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-10-29 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-07-30 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |